{"entity":{"id":"bob-li","kind":"person","name":"Bob T. Li","aka":[],"tldr":"Ran the trials that made trastuzumab deruxtecan the first HER2-directed drug for lung cancer.","summary":"Bob T. Li is a Medical Oncologist in Thoracic Oncology and Physician Ambassador to China and Asia-Pacific at Memorial Sloan Kettering Cancer Center. He is known for leading DESTINY-Lung01, the trial that established trastuzumab deruxtecan as the first HER2-directed drug for HER2-mutant non-small-cell lung cancer, and for early studies of HER2-directed therapy in lung cancer. His selected paper reports trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. He continues to work on antibody-drug conjugates and early drug development while leading MSK's partnerships across the Asia-Pacific region.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20BT%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["adc"],"targets":["her2"],"drugs":["trastuzumab-deruxtecan"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Physician Ambassador to China and Asia-Pacific; Medical Oncologist, Thoracic Oncology","institutionId":"mskcc","specialisms":["HER2-mutant lung cancer","Antibody-drug conjugates","Early drug development"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20BT%5BAuthor%5D"}],"papers":[{"title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","journal":"New England Journal of Medicine","year":2022,"url":"https://doi.org/10.1056/NEJMoa2112431","doi":"10.1056/NEJMoa2112431"}],"orcid":"0000-0001-6661-8733"},"route":"/people/bob-li/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"destiny-lung01","kind":"trial","name":"DESTINY-Lung01","route":"/trials/destiny-lung01/"}]}}